MOZ/MORF Inhibitor

PF-9363 (CTx-648) is a first-in-class potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancer.

WM-8014 is an inhibitor of MOZ, a member of histone acetyltransferases, with an IC₅₀ of 55 nM.

WM-1119, a chemical probe, is a highly potent and selective KAT6A inhibitor, with an IC₅₀ of 0.25 μM for KAT6A in lymphoma cells, the binding K_D values of WM-1119 with KAT6A, KAT5 and KAT7 are 2 nM, 2.2 μM, 0.5 μM , respectively.

MOZ-IN-3 is an orally active KAT6A (MOZ) inhibitor with an IC₅₀ of 0.03 μM against human targets, and it exhibits high selectivity over other MYST family histone acetyltransferases. MOZ-IN-3 modulates monocyte function, exerts anti-tumor effects, increases the nucleocytoplasmic ratio, and enhances cellular resistance to chemotherapeutic drug-induced cell death. MOZ-IN-3 is applicable to leukemia-related research.

MOZ-IN-2 is an inhibitor of protein MOZ, a member of histone acetyltransferases, with an IC₅₀ of 125 μM.

KAT6A/KAT7-IN-4 is a KAT6A and KAT7 inhibitor. KAT6A/KAT7-IN-4 has IC₅₀ values of both ≤ 1 nM for KAT6A and KAT7. KAT6A/KAT7-IN-4 can inhibit the acetylation of H3K14 and H3K23. KAT6A/KAT7-IN-4 also inhibits tumor cell proliferation, with an IC₅₀ of ≤ 100 nM for CAMA-1. KAT6A/KAT7-IN-4 can be used in the study of breast cancer.